Angela Hong

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

Bryan Burmeister, Michael A. Henderson, Jill Ainslie et al. · The Lancet Oncology · 2012 · 293 citations

Medicine, Oncology, Surgery +17

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

Michael A. Henderson, Bryan Burmeister, Jill Ainslie et al. · The Lancet Oncology · 2015 · 224 citations

Medicine, Oncology, Surgery +14

Desmoplastic neurotropic melanoma

James Y. Chen, George Hruby, Richard A. Scolyer et al. · Cancer · 2008 · 155 citations

Medicine, Oncology, Surgery +14

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

Elizabeth Liniker, Alexander M. Menzies, Benjamin Y. Kong et al. · OncoImmunology · 2016 · 151 citations · Full text

Medicine, Oncology, Radiation Oncology +17